Leerink Partnrs Weighs in on Galecto FY2029 Earnings

Galecto, Inc. (NASDAQ:GLTO) – Investment analysts at Leerink Partnrs issued their FY2029 earnings per share estimates for shares of Galecto in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($4.14) for the year. The consensus estimate for Galecto’s current full-year earnings is ($15.59) per share.

Separately, Oppenheimer lifted their price objective on shares of Galecto from $9.00 to $10.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th.

Galecto Price Performance

Shares of Galecto stock opened at $4.98 on Friday. Galecto has a 52 week low of $4.40 and a 52 week high of $23.50. The business has a 50 day moving average price of $5.20 and a 200-day moving average price of $8.48.

About Galecto

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.